Microparticles comprising somatostatin analogues

Abstract

Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.

1 . A method of treating a disease or disorder with an aetiology comprising or associated with excess GH- and/or IGF-1 secretion in a subject in need thereof which comprises administering microparticles where said microparticles comprising cyclo[{4-(NH 2 —C 2 H 4 —NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] in free form, salt form or protected form embedded in a polymer matrix wherein the polymer matrix comprises a linear and a star polylactide-co-glycolide. 
     
     
         2 . A method according to  claim 1  wherein the cyclo[{4-(NH 2 —C 2 H 4 —NH—CO—O—) Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] is in pamoate salt form. 
     
     
         3 . A method according to  claim 1  wherein the polymer matrix comprises a linear polylactide-co-glycolide polymer and a star polylactide-co-glycolide polymer having a weight average molecular weight of about 50,000 Da. 
     
     
         4 . A method according to  claim 1  wherein the ratio of linear to star polylactide-co-glycolide is 50:50. 
     
     
         5 . A method according to  claim 1  wherein the cyclo[{4-(NH 2 —C 2 H 4 —NH—CO—O—) Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] is an amorphous powder having a particle size less than about 5 microns. 
     
     
         6 . A method according to  claim 1  where said microparticles further comprising a surfactant, a porosity influencing agent and/or a basic salt. 
     
     
         7 . A method of treating a disease or disorder with an aetiology comprising or associated with excess GH- and/or IGF-1 secretion in a subject in need thereof which comprises administering a composition comprising microparticles where said microparticles comprising cyclo[{4-(NH 2 —C 2 H 4 —NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] in free form, salt form or protected form embedded in a polymer matrix wherein the polymer matrix comprises a linear and a star polylactide-co-glycolide. and a water-based vehicle comprising a wetting agent. 
     
     
         8 . A method according to  claim 7  wherein the wetting agent comprises a poloxamer and/or a polyoxyethylene-sorbitan-fatty acid ester. 
     
     
         9 . A method according to  claim 7  wherein the vehicle comprises a tonicity agent. 
     
     
         10 . A method according to  claim 7  wherein the vehicle comprises a viscosity increasing agent.